Confluent and reticulated papillomatosis associated with polycystic ovary syndrome treated with a combined contraceptive containing drospirenone
Ozdemir, S.; Ozdemir, M.; Toy, H.
Journal of the European Academy of Dermatology and Venereology Jeadv 23(3): 358-359
2009
ISSN/ISBN: 1468-3083 PMID: 18540980 DOI: 10.1111/j.1468-3083.2008.02847.xDocument Number: 207022
Document emailed within 0-6 h
Related Documents
Kriplani, A.; Periyasamy, A.J.; Agarwal, N.; Kulshrestha, V.; Kumar, A.; Ammini, A.C. 2010: Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome Contraception 82(2): 139-146Battaglia, C.; Mancini, F.; Fabbri, R.; Persico, N.; Busacchi, P.; Facchinetti, F.; Venturoli, S. 2010: Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. a prospective, randomized, pilot study Fertility and Sterility 94(4): 1417-1425
Chang, S.N.; Kim, S.C.; Lee, S.H.; Lee, W.S. 1996: Minocycline treatment for confluent and reticulated papillomatosis Cutis 57(6): 454-457
Bhattacharya, S.M.; Jha, A.; DasMukhopadhyay, L. 2016: Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 132(2): 210-213
Bhattacharya, S.M.; Jha, A. 2012: Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome Fertility and Sterility 98(4): 1053-1059
Kahraman, K.; Sükür, Y.E.; Atabekoğlu, C.S.; Ateş, C.; Taşkın, S.; Cetinkaya, S.E.; Tolunay, H.E.; Ozmen, B.; Sönmezer, M.; Berker, B.ül. 2014: Comparison of two oral contraceptive forms containing cyproterone acetate and drospirenone in the treatment of patients with polycystic ovary syndrome: a randomized clinical trial Archives of Gynecology and Obstetrics 290(2): 321-328
Macut, D.; Božić Antić, I.; Nestorov, J.; Topalović, V.; Bjekić Macut, J.; Panidis, D.; Kastratović Kotlica, B.; Papadakis, E.; Matić, G.; Vojnović Milutinović, D. 2015: The influence of combined oral contraceptives containing drospirenone on hypothalamic-pituitary-adrenocortical axis activity and glucocorticoid receptor expression and function in women with polycystic ovary syndrome Hormones 14(1): 109-117
Minozzi, M.; Costantino, D.; Guaraldi, C.; Unfer, V. 2011: The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 27(11): 920-924
Namli Kalem, M.üb.; Hizli, D.; Kamalak, Z.; Kösüs, A.; Kösüs, N.; Turhan, N.ün.; Kafali, H. 2016: Effect of combined oral contraceptive use on serum 25-hydroxy vitamin D levels and ultrasound parameters in patients with polycystic ovary syndrome Gynecological Endocrinology: the Official Journal of the International Society of Gynecological Endocrinology 32(4): 281-284
Costello, M.; Shrestha, B.; Eden, J.; Sjoblom, P.; Johnson, N. 2007: Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome Cochrane Database of Systematic Reviews 1: Cd005552
Oner, G.; Muderris, I.I. 2011: A prospective randomized trial comparing low-dose ethinyl estradiol and drospirenone 24/4 combined oral contraceptive vs. ethinyl estradiol and drospirenone 21/7 combined oral contraceptive in the treatment of hirsutism Contraception 84(5): 508-511
Chen, R.; Wang, C.; Yan, Q.-Y. 2014: Observation on therapeutic effect of polycystic ovary syndrome of damp-phlegm constitution treated with embedding therapy on back-shu points and front-mu points combined with needle-pricking therapy on Sifeng (EX-UE 10) Zhongguo Zhen Jiu 34(4): 355-358
Moran, L.J.; Thomson, R.L.; Buckley, J.D.; Noakes, M.; Clifton, P.M.; Norman, R.J.; Brinkworth, G.D. 2015: Steroidal contraceptive use is associated with lower bone mineral density in polycystic ovary syndrome Endocrine 50(3): 811-815
Harmanci, A.; Cinar, N.; Bayraktar, M.; Yildiz, B.O. 2013: Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome Clinical Endocrinology 78(1): 120-125
Raj, S.G.; Raj, M.H.; Talbert, L.M.; Sloan, C.S.; Hicks, B. 1982: Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome Obstetrics and Gynecology 60(1): 15-19
Iwata, M.Chiharu.; Porquere, L.; Sorpreso, I.C.Espósito.; Baracat, E.C.; Soares Júnior, Jé.Maria. 2015: Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome Revista da Associacao Medica Brasileira 61(3): 215-219
Kasapoglu, T. 2013: Do oral contraceptive pills really protect against venous thromboembolism, especially in polycystic ovary syndrome patients? Prescription bias or not? American Journal of Obstetrics and Gynecology 209(1): 73-74
Banaszewska, B.; Spaczyński, R.Z.; Ozegowska, K.; Pawelczyk, L. 2011: The influence of low-dose oral contraceptive pill on clinical and metabolic parameters in young women with polycystic ovary syndrome Ginekologia Polska 82(6): 430-435
Cinar, N.; Harmanci, A.; Demir, B.; Yildiz, B.O. 2012: Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study Human Reproduction 27(6): 1840-1845
Vieira, C.S.; Martins, W.P.; Fernandes, J.ín.B.F.ça.; Soares, G.M.; dos Reis, R.M.; de Sá, M.F.S.; Ferriani, R.A. 2012: The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome Contraception 86(3): 268-275